Extended Data Fig. 2: Forest plot of known biomarkers in urothelial carcinoma, renal cell carcinoma and prostate cancer. | Nature Medicine

Extended Data Fig. 2: Forest plot of known biomarkers in urothelial carcinoma, renal cell carcinoma and prostate cancer.

From: Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Extended Data Fig. 2

Biomarkers shown among urothelial carcinoma (IMvigor210), renal cell carcinoma (IMmotion150), and prostate cancer (IMbassador250) for PFS. DDR, DNA damage response; PD-L1, programmed death- ligand 1; PFS, progression-free survival; Teff, effector T cell, TMB, tumor mutational burden. Med refers to median PFS in months. HRs and CIs were calculated using Cox proportional hazards regression model, and P values were calculated using unstratified log-rank test without adjustment for multiplicity.

Back to article page